Milken Family Foundation Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2008
NCT00524134
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Milken Institute | Milken Institute Center for Strategic Philanthropy

Active Ingredients

Drugs in Phase 3 Trials (1)

carvedilol (coreg) (1 trial)

Drugs in Phase 2 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Other Trials (4)

bifidobacterium bifidum (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus rhamnosus (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Drug Resistant Epilepsy (Phase 3)

Epilepsy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6